BTMD

TentativeAI Memo

biote

As of 2026-08-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings miss and outlook reset • 2026-08-05

Base target: $1 / p=45% prob

Biggest risk

The recall caused weaker procedure revenue, lower margins, a quarterly loss, and reduced EBITDA. Procedure revenue is still expected to decline year over year in Q3 and Q4, while execution, clinic retention, legal costs, and leadership transition remain concerns.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Recall resolution, normalized Asteria inventory, second-half procedure improvement, and mid-to-high-single-digit dietary-supplement growth could restore margins and operating momentum.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-18

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recall normalization and procedure recovery
Recall resolution, normalized Asteria inventory, second-half procedure improvement, and mid-to-high-single-digit dietary-supplement growth could restore margins and operating momentum.
The packet shows a median analyst target of $2.612, implying substantial upside from $1.30, but the analyst target count is unavailable.

BearKey bullets

Gross-margin recovery depends on inventory normalization and lower-cost internal manufacturing.
Low coverage, small market capitalization, and unvalidated peers limit valuation and revision confidence.
Procedure revenue is expected to remain negative year over year in Q3 and Q4.

WatchKey bullets

Q2 earnings miss and outlook reset

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +101% / -42%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $1 (p=45%)Bear Target: $1 (p=30%)

Commentary

News tone is negative-to-mixed, centered on the recall, Q2 earnings pressure, and lower full-year guidance. The company source confirms sequential second-half improvement expectations, but the market has limited evidence that the recovery is underway. Analyst revision data and direct peer valuation support are limited; social, options, short-interest, and employee data are unavailable.

As of 2026-08-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Recall resolution, normalized Asteria inventory, second-half procedure improvement, and mid-to-high-single-digit dietary-supplement growth could restore margins and operating momentum.

Bear Case

Drivers

Scannable catalysts and supporting factors

Recall normalization and procedure recovery

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-08-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.55

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-08-05
Q2 earnings miss and outlook reset
The SEC-reported Q2 results showed revenue of $44.2 million, a 9.5% year-over-year decline, procedure revenue down 13.9%, gross margin at 65.4%, and adjusted EBITDA margin at 12.6%. Stored Zacks earnings context reports break-even adjusted EPS versus $0.03 consensus and revenue 5.71% below consensus. Management revised 2026 guidance to revenue above $175 million and adjusted EBITDA above $25 million. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-06]
Prob 100.00% • Move -15.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

Recall normalization and procedure recovery
2026-11-16
Management expects sequential procedure-revenue improvement in Q3 and Q4 as Asteria Health inventory normalizes, but still expects negative year-over-year procedure growth in both periods. Margin recovery depends on reduced reliance on higher-cost replacement suppliers and improved manufacturing efficiency. [#SEC-8K-2026-08-05]
Prob 60% • Move 18% • Priced-in 55%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Gross-margin recovery depends on inventory normalization and lower-cost internal manufacturing.
Low coverage, small market capitalization, and unvalidated peers limit valuation and revision confidence.
Procedure revenue is expected to remain negative year over year in Q3 and Q4.
Recall-related supply disruption may persist longer than expected.
The recovery plan has not yet translated into reported growth, and execution risk remains elevated.

Peers

Symbol	Summary
ATYR	Loose same-sector, similar-market-cap screening candidate; no direct operating comparability was validated and it is excluded from core valuation comparison.
CNTX	Loose same-sector, similar-market-cap screening candidate; no direct operating comparability was validated and it is excluded from core valuation comparison.
MREO	Loose same-sector, similar-market-cap screening candidate; no direct operating comparability was validated and it is excluded from core valuation comparison.
SCYX	Loose same-sector, similar-market-cap screening candidate; no direct operating comparability was validated and it is excluded from core valuation comparison.
TIL	Loose same-sector, similar-market-cap screening candidate; no direct operating comparability was validated and it is excluded from core valuation comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-18

Loading AI feed…

Symbol

Summary

ATYR